Vapotherm Inc. Announces $30 Million Financing Round - Gilde Healthcare

Vapotherm Inc. Announces $30 Million Financing Round

November 24, 2015

EXETER, NH,– Vapotherm, Inc., announced today it closed a $30 million equity financing last month. The first tranche of $15 million closed on October 30, 2015, and the second tranche is scheduled to close in September 2016. Arnerich Massena led the financing round, which included one new investor, Perceptive Advisors, along with current investors Gilde Healthcare Partners, Morgenthaler Ventures, QuestMark Partners, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.

“We are delighted by our investors’ continued support of Vapotherm. Their support helps us provide High Flow Therapy, our unique respiratory solution to improve clinical and economic outcomes for customers and the patients they serve,” said Joe Army, President and CEO of Vapotherm.

Tony Arnerich, CEO of Arnerich Massena, commented “We are enthusiastic about continuing to support Vapotherm. This new capital will help the company continue the expansion of the U.S. field organization, develop new products and expand in select International markets.”

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 700,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vtherm.com.

Contact: John Landry, VP & CFO
T: (603) 658-0011

Gilde Healthcare establishes world-leading Impact Council

Gilde Healthcare, the specialized healthcare investor with €2 billion raised in dedicated sector funds, today announced the establishment of the Gilde Healthcare Impact Council. Chaired by Professor Guido Rasi, former Executive Director of the European...
November 29, 2022

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022